Danger ahead: Watch out for indirect comparisons!

Journal of the American College of Cardiology

Volumn 60, Issue 8, 2012, Pages 747-748

  Cannon, Christopher P ^a   Kohli, Payal ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anticoagulation; atrial fibrillation; bleeding; stroke

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DATA ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; EMBOLISM; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; MORTALITY; NOTE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 84865140421     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.05.012     Document Type: Editorial

References (10)

1. S.J. Connolly, M.D. Ezekowitz, S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
2. M.R. Patel, K.W. Mahaffey, J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
3. C.B. Granger, J.H. Alexander, J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
4. C.T. Ruff, R.P. Giugliano, E.M. Antman Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
5. G.Y.H. Lip, T.B. Larsen, F. Skjøth, K.H. Rasmussen Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 2012 738 746
6. R.G. Wilcox, G. von der Lippe, C.G. Olsson, G. Jensen, A.M. Skene, J.R. Hampton Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction Anglo-Scandinavian Study of Early Thrombolysis (ASSET) Lancet 2 1988 525 530
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
8. AIMS Trial Study Group Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study Lancet 335 1990 427 431
9. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction Lancet 339 1992 753 770
10. J.L. Mega A new era for anticoagulation in atrial fibrillation N Engl J Med 365 2011 1052 1054